Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Line Genomics AB
AB
Active
Org 5594455106
Sverkersgatan 6, 126 55
Hägersten
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2023 · 2 years old
0 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Line Genomics AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2024
EBITDA
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2024
Income statement
SEK thousands
Item
2024
Revenue
0
Staff expenses
—
EBITDA
−4
Depreciation & amort.
—
EBIT
−4
Net financials
—
Profit before tax
−4
Tax
—
Net profit
−4
Balance sheet
SEK thousands
Item
2024
Total assets
140
Equity
140
Long-term debt
—
Short-term debt
0
Total debt
—
Financial ratios
5-year trend
EBITDA margin
-365700.0%
This company
15.8%
Market median
-2314657% vs market
2024
2024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
2024
2024
Return on equity
-2.6%
This company
18.4%
Market median
-114% vs market
2024
2024
Net profit margin
-365700.0%
This company
8.1%
Market median
-4514915% vs market
2024
2024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2024
2024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
2024
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2023-08-22 – 2024-12-31
View
PDF
More on Line Genomics AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
